


Inhibikase Therapeutics, Inc. (IKT)

Nasdaq; healthcare; SIC 2836, Biological Products, (No Diagnostic Substances); CIK 0001750149

Inhibikase Therapeutics, Inc.		
IKT; healthcare		
Grade	None 5 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.87 AUC filers with \$120M to \$591M assets; 95% interval 0.83 to 0.90; 206 events, 2020 to 2025	
Peer failure rate	1.03% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	\$120M to \$591M assets total assets \$181.2M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	dilution, thin data, degenerate inputs; fortress balance sheet not computable: short runway, distress	
Inputs computable	5 of 14	
Graded from	filings received through Mar 26, 2026 197 days before the rescan; latest periodic filing 10-Q received Aug 11, 2026	
Last close	\$1.91 2026-10-08; market equity \$266.5M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received Mar 26, 2026

We are a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension ("PAH"), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as "c-Kit", has been implicated. Our lead product candidate is IKT-001, a prodrug of imatinib mesylate ("imatinib"), for PAH which is an orphan indication.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 30.5						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			required facts have no common fiscal period end
Accruals ratio		(14.6%)	(6.6%)	30.5	811	2025-12-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 2.8						
Twelve-month failure probability		not computable	0.07%			latest liabilities, cash plus short-term investments, book equity, and shares are required
Altman Z double-prime		23.60	(0.31)	1.9	756	2025-12-31
Net debt to EBITDA		not computable	1.82x			EBITDA must exceed \$100,000 interest expense must exceed \$100,000
Interest coverage		not computable	(4.51x)			
Current ratio		21.70x	2.96x	3.8	839	2025-12-31
Growth and financing, sleeve percentile 41.4						
Revenue growth, three-year compound		not computable	10.0%			current value must be positive and the base must exceed \$100,000
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			pretax income must exceed the validity floor and imply a 0%-100% tax rate
Asset growth, three years		93.7%	2.1%	2.4	704	2025-12-31
Net share issuance, one year		77.6%	2.5%	80.4	634	2026-03-20

Warnings

4 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 77.6%
Thin data	5 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor
Fortress balance sheet	cash minus debt is 8,818,216 USD; Altman Z is not used

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	42.6%	8.0%	72
Distance from 52-week high	(24.2%)	(31.4%)	59
EBIT to enterprise value	(59.0%)	(1.5%)	12
Free cash flow yield	(10.4%)	(1.0%)	30
Book value to price	0.58	0.28	73
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	0.14	(0.14)	72

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	59 (10-Q received Aug 11, 2026)
Median daily dollar volume, 63 sessions	\$1.1M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$48.3M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$27.8M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
3	assets	us-gaap:Assets	\$181.2M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
4	assets	us-gaap:Assets	\$98.6M	2024-12-31	2026-03-26	10-K	0001193125-26-126371
5	current assets	us-gaap:AssetsCurrent	\$180.1M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
6	current liabilities	us-gaap:LiabilitiesCurrent	\$8.3M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$142.7M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
8	operating income	us-gaap:OperatingIncomeLoss	-\$52.0M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
9	book equity	us-gaap:StockholdersEquity	\$172.9M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
10	liabilities	us-gaap:Liabilities	\$8.3M	2025-12-31	2026-03-26	10-K	0001193125-26-126371
11	total debt	us-gaap:LongTermDebt	\$381,784	2023-12-31	2024-03-27	10-K	0000950170-24-037160
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	\$9.2M	2023-12-31	2025-03-27	10-K	0000950170-25-046096
13	operating income	us-gaap:OperatingIncomeLoss	-\$20.1M	2023-12-31	2025-03-27	10-K	0000950170-25-046096
14	depreciation amortization	us-gaap:Depreciation	\$177,398	2023-12-31	2025-03-27	10-K	0000950170-25-046096
15	operating income	us-gaap:OperatingIncomeLoss	-\$14.8M	2021-12-31	2023-03-31	10-K	0000950170-23-011133
16	interest expense	us-gaap:InterestExpense	\$19,923	2021-12-31	2022-03-31	10-K	0000950170-22-005203
17	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$0	2024-12-31	2025-03-27	10-K	0000950170-25-046096
18	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$260,501	2023-12-31	2025-03-27	10-K	0000950170-25-046096
19	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$123,440	2022-12-31	2024-03-27	10-K	0000950170-24-037160
20	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$3.1M	2021-12-31	2023-03-31	10-K	0000950170-23-011133
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$13,399	2025-12-31	2026-03-26	10-K	0001193125-26-126371
22	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$19.1M	2024-12-31	2026-03-26	10-K	0001193125-26-126371
23	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$0	2024-12-31	2026-03-26	10-K	0001193125-26-126371

24	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$18.1M	2023-12-31	2025-03-27	10-K	0000950170-25-046096
25	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14,238	2023-12-31	2025-03-27	10-K	0000950170-25-046096
26	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$17.4M	2022-12-31	2024-03-27	10-K	0000950170-24-037160
27	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$243,255	2022-12-31	2024-03-27	10-K	0000950170-24-037160
28	depreciation amortization	us-gaap:Depreciation	\$60,499	2025-12-31	2026-03-26	10-K	0001193125-26-126371
29	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$18,259	2025-12-31	2026-03-26	10-K	0001193125-26-126371
30	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2025-12-31	2026-03-26	10-K	0001193125-26-126371
31	current assets	us-gaap:AssetsCurrent	\$98.5M	2024-12-31	2026-03-26	10-K	0001193125-26-126371
32	current liabilities	us-gaap:LiabilitiesCurrent	\$3.7M	2024-12-31	2026-03-26	10-K	0001193125-26-126371
33	assets	us-gaap:Assets	\$14.5M	2023-12-31	2025-03-27	10-K	0000950170-25-046096
34	assets	us-gaap:Assets	\$24.9M	2022-12-31	2024-03-27	10-K	0000950170-24-037160
35	shares outstanding	dei:EntityCommonStockSharesOutstanding	132,032,636	2026-03-20	2026-03-26	10-K	0001193125-26-126371
36	shares outstanding	dei:EntityCommonStockSharesOutstanding	74,341,540	2025-04-15	2025-04-25	10-K/A	0000950170-25-058693